Under a tenth of people who could benefit from GLP-1 drugs like Wegovy can access them, caution the WHO as it releases its first advice on the drugs.
With in excess of 1,000,000,000 individuals worldwide now living with obesity, it is urging broader and more equitable availability to GLP-1 medication.
According to estimates, in excess of 2,000,000,000 will be living with obesity by 2030 unless action is taken.
"The new guidelines recognises that excess weight is a chronic disease that can be managed with holistic and continuous care," said the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are significant obstacles to universal availability to the jabs that can aid individuals in losing substantial weight, says the body.
Skinny Jab Supply Crisis
Even in the current best projected outlook, the supply of these medications might only reach about 100 million people – less than 10% of the global need, as stated by the WHO.
The recommendation encourages countries and companies to increase availability, by measures including licensing agreements.
Exclusive production rights on a key compound – the core component of the drug Wegovy – is scheduled to end in a number of nations in 2026.
The Way Obesity Injections Work
The injections mimick a body's own hormone to reduce digestion speed, suppress the appetite and increase feelings of fullness so individuals consume fewer calories.
People commonly start to lose weight after several weeks of starting on the regular doses.
Evidence points to people may regain a significant portion after a year of discontinuing the treatment, as their normal hunger return.
To be above a healthy weight raises your risk for experiencing diseases, like type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies.
Excess weight impacts individuals in every country and was associated with 3.7 million fatalities worldwide in 2024, as per the health agency.
